Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Carcinoma, Non-Small-Cell Lung 1C04.588.274.476.411.307 1Adenocarcinoma 1

Interventions

devimistat 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × C04.588.274.476.411.307 × devimistat × Clear all
NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Cornerstone Pharmaceuticals

Phase 1 Withdrawn

C04.588.274.476.411.307

Data powered by HemOnc (CC BY 4.0) Colophon âš¡